Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma

MLA

Young Mi Hong, et al. “Systemic Immune-Inflammation Index Predicts Prognosis of Sequential Therapy with Sorafenib and Regorafenib in Hepatocellular Carcinoma.” BMC Cancer, vol. 21, no. 1, May 2021, pp. 1–8. EBSCOhost, https://doi.org/10.1186/s12885-021-08124-9.

APA

Young Mi Hong, K. T. Yoon, & Mong Cho. (2021). Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma. BMC Cancer, 21(1), 1–8. https://doi.org/10.1186/s12885-021-08124-9

Chicago

Young Mi Hong, K. T. Yoon, and Mong Cho. 2021. “Systemic Immune-Inflammation Index Predicts Prognosis of Sequential Therapy with Sorafenib and Regorafenib in Hepatocellular Carcinoma.” BMC Cancer 21 (1): 1–8. doi:10.1186/s12885-021-08124-9.